You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Proton pump inhibitors and the risk for gastric cancer: possible confounding by serum vitamin B 12
  1. Itai Gueta1,
  2. Hillel Halkin1,2,
  3. Noa Markovits1,2,
  4. Ronen Loebstein1,2
  1. 1 The Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center, Tel Hashomer, Israel
  2. 2 Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  1. Correspondence to Dr Itai Gueta, Sheba Medical Center, Tel Hashomer, Ramat Gan, 5262000, Israel; itai.gueta{at}sheba.health.gov.il

https://doi.org/10.1136/gutjnl-2017-315695

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the article by Cheung et al 1 reporting an increased risk of gastric cancer with long-term exposure to proton pump inhibitors (PPI) following Helicobacter pylori (HP) eradication. Several recent reports and a meta-analysis have also demonstrated this association.2 3 The present study, using strict exclusion criteria, was able to adjust for the confounding effect of previous HP infection and eradication, demonstrating a PPI exposure-dependent escalating risk for non-cardia gastric cancer (NCGC) in previously infected patients. The authors suggest that the profound acid suppression by PPIs worsens the atrophic gastritis induced by HP infection, …

    View Full Text

    Footnotes

    • Contributors IG and HH raised the conception and performed the literature survey. All authors contributed to the writing of the letter. IG is the guarantor.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.